DBV Technologies | DBVT - Selling And Administration Expenses

Stock Price
21.14
Daily Change
-0.32 -1.49%
Monthly
-2.45%
Yearly
381.00%
Q1 Forecast
20.91

DBV Technologies reported $3.63M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Galectin Therapeutics USD 1.48M 110K Jun/2024
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
United Therapeutics USD 152M 60.5M Sep/2025